Abstract
The antidepressant effects of neuroactive steroid positive allosteric modulators of GABAA receptors (GABAAR PAMs) likely involve extrasynaptic GABAAR. PRAX-114 is a novel GABAAR PAM with preference for extrasynaptic GABAAR, which is hypothesized to improve tolerability. Here we compared the therapeutic window of PRAX-114 and zuranolone, using EEG β-power as a biomarker of GABAAR potentiation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
